| Introduction |
|
|
1 Platelet infrastructure Morphology |
|
|
1 | (6) |
|
2 Platelet Morphology and Function |
|
|
7 | (15) |
|
Introduction to Platelets |
|
|
7 | (5) |
|
|
|
12 | (1) |
|
|
|
12 | (1) |
|
Fluorescent and Confocal Microscopy |
|
|
13 | (1) |
|
Platelet Aggregometry Studies |
|
|
14 | (4) |
|
|
|
18 | (4) |
|
3 Platelet Morphology and Dysfunction |
|
|
22 | (14) |
|
|
|
22 | (2) |
|
Common Platelet Disorders, Biochemical and Clinical Findings |
|
|
24 | (5) |
|
Miscellaneous Dysfunction of Platelet Function |
|
|
29 | (7) |
|
|
|
36 | (10) |
|
5 Platelet Activation Mechanisms |
|
|
46 | (9) |
|
Signaling Pathways via GTP-Binding Protein-Coupled Receptors |
|
|
47 | (2) |
|
Phosphoinositide Metabolism and Platelet Activation |
|
|
49 | (1) |
|
Lipid Phosphate Phosphatases and Platelet Activation |
|
|
49 | (1) |
|
Protein Phosphorylations and Platelet Activation |
|
|
50 | (5) |
|
6 Role of Calcium in Platelet Activation |
|
|
55 | (5) |
|
7 Eicosanoid Metabolism and Platelet Function |
|
|
60 | (10) |
|
8 Calcium Modulation by Cyclic Nucleotides |
|
|
70 | (7) |
|
9 Pharmacology of Antiplatelet Drugs |
|
|
77 | (11) |
|
Agents Modulating Platelet Function |
|
|
79 | (9) |
|
10 Antiplatelet Therapies |
|
|
88 | (13) |
|
|
|
89 | (1) |
|
Clinical Conditions Needing Antiplatelet Therapy |
|
|
90 | (1) |
|
Pharmacological Approaches for Development of Antiplatelet Drugs |
|
|
90 | (1) |
|
Clinical Complications Needing Antiplatelet Therapies |
|
|
91 | (2) |
|
Clinical Trials of Antiplatelet Drugs |
|
|
93 | (8) |
|
|
|
101 | (19) |
|
|
|
102 | (1) |
|
Arachidonic Acid Metabolism |
|
|
102 | (1) |
|
|
|
103 | (3) |
|
|
|
106 | (2) |
|
Prevalence of Aspirin Resistance |
|
|
108 | (12) |
|
12 Platelet Dysfunctions Associated with Diabetes Mellitus |
|
|
120 | (17) |
|
|
|
120 | (1) |
|
Arachidonic Acid Metabolism |
|
|
121 | (1) |
|
|
|
121 | (3) |
|
|
|
124 | (2) |
|
|
|
126 | (2) |
|
Blood Cells and Blood Components |
|
|
128 | (1) |
|
Role of Platelets in Vascular Pathology |
|
|
128 | (1) |
|
Management of Hematological Parameters |
|
|
129 | (8) |
|
13 Platelet Hyperfunction as a Risk Promoter for Acute Coronary Events |
|
|
137 | (12) |
|
|
|
138 | (1) |
|
Activation of Circulating Blood Cells and Inflammation |
|
|
139 | (1) |
|
|
|
139 | (1) |
|
Hormones, Stress, and Acute Coronary Events |
|
|
140 | (2) |
|
|
|
142 | (1) |
|
Need for a Point-of-Care Assay for Monitoring Antiplatelet and Antithrombotic Therapies |
|
|
143 | (6) |
|
14 Epinephrine-induced Platelet Membrane Modulation |
|
|
149 | (17) |
|
Mechanism of Membrane Modulation |
|
|
149 | (17) |
|
15 Platelet-Vessel Wall Interactions |
|
|
166 | (13) |
|
Blood Vessel Covered by a Monolayer of Endothelial Cells |
|
|
166 | (1) |
|
|
|
167 | (1) |
|
|
|
168 | (11) |
|
16 Blood Biocompatibility Studies |
|
|
179 | (24) |
|
Blood Biocompatibility Laboratory (BBL), Medical School, University of Minnesota |
|
|
179 | (1) |
|
|
|
179 | (1) |
|
Stroke Research: Platelet and Blood Clot Studies |
|
|
180 | (1) |
|
National Institute of Health Research Grants |
|
|
180 | (1) |
|
Assays Available for Studies at BBL |
|
|
181 | (2) |
|
Role of Platelets in Blood-Biomaterial Interactions |
|
|
183 | (2) |
|
Validation of Blood-Biomaterial Interactions with Pyrolytic Carbon Bileaflet Heart Valves |
|
|
185 | (2) |
|
Exposure of Mechanical Pyrolytic Carbon Leaflets to Human Blood Under Flow Conditions |
|
|
187 | (1) |
|
Exposure of Fully Assembled Heart Valves to Human Blood Under Flow Conditions |
|
|
188 | (6) |
|
Novel Nanoparticle-based Theranostics: Expectations and Limitations |
|
|
194 | (1) |
|
Nano- and Microparticles in Cardiovascular Drug Delivery |
|
|
195 | (8) |
| Afterword |
|
203 | (2) |
| Bibliography |
|
205 | (46) |
| Index |
|
251 | |
